去甲肾上腺素等效评分对脓毒症患者28天死亡风险的预测价值:一项回顾性队列研究
本研究基于MIMIC-IV 2.2数据库开展回顾性队列研究,纳入7 744例符合Sepsis-3诊断标准且在诊断后6小时内接受血管升压药治疗的脓毒症患者,按28天结局分为存活组(5 997例)和死亡组(1 747例),28天死亡率为22.6%。多因素Cox回归显示,去甲肾上腺素等效评分(HR=1.040,95%CI 1.021-1.060,P<0.001)是28天死亡的独立危险因素。ROC曲线分析显示,去甲肾上腺素等效评分预测28天死亡的AUC为0.743(95%CI 0.730-0.756),与APACHE II评分(AUC=0.742)和平均动脉压/去甲肾上腺素等效评分比值(AUC=0.738)相当(均P>0.05),优于SOFA评分(AUC=0.609)、CCI评分(AUC=0.658)、休克指数(AUC=0.613)和舒张压/去甲肾上腺素等效评分比值(AUC=0.735)(均P<0.05)。以ROC曲线确定的截断值分层后,去甲肾上腺素等效评分≤0.120的患者28天累积生存率显著高于>0.120者(Log-Rank检验:χ2=832.449,P<0.001)。
要点
- 在脓毒症诊断后6小时内接受血管活性药物治疗的患者中,去甲肾上腺素等效评分是28天死亡的独立危险因素(HR=1.040,95%CI 1.021-1.060,P<0.001)。
- 去甲肾上腺素等效评分预测28天死亡的AUC为0.743(95%CI 0.730-0.756),与APACHE II评分(AUC=0.742)和平均动脉压/去甲肾上腺素等效评分比值(AUC=0.738)相当(均P>0.05)。
- 去甲肾上腺素等效评分预测价值优于SOFA评分(AUC=0.609)、CCI评分(AUC=0.658)、休克指数(AUC=0.613)和舒张压/去甲肾上腺素等效评分比值(AUC=0.735)(均P<0.05)。
- 去甲肾上腺素等效评分≤0.120的患者28天累积生存率显著高于>0.120者(Log-Rank检验:χ2=832.449,P<0.001)。
- APACHE II评分≤22.5的患者28天累积生存率显著高于>22.5者(Log-Rank检验:χ2=848.600,P<0.001)。
适用人群与场景
- 基于MIMIC-IV 2.2数据库中符合Sepsis-3诊断标准、且在脓毒症或脓毒性休克诊断后6小时内接受血管活性药物治疗的脓毒症患者。
- 按28天结局分为存活组(5 997例)和死亡组(1 747例)。
诊断标准与关键阈值
- Sepsis-3诊断标准。
- 去甲肾上腺素等效评分截断值0.120:≤0.120者28天累积生存率显著高于>0.120者(Log-Rank检验:χ2=832.449,P<0.001)。
- APACHE II评分截断值22.5:≤22.5者28天累积生存率显著高于>22.5者(Log-Rank检验:χ2=848.600,P<0.001)。
研究设计与关键结果
- 回顾性队列研究,基于MIMIC-IV 2.2数据库,纳入7 744例符合Sepsis-3诊断标准且在诊断后6小时内接受血管升压药治疗的脓毒症患者,28天死亡率为22.6%(死亡1 747例,存活5 997例)。
- 多因素Cox回归显示,去甲肾上腺素等效评分(HR=1.040,95%CI 1.021-1.060,P<0.001)、休克指数(HR=1.840,95%CI 1.675-2.022,P<0.001)、APACHE II评分(HR=1.076,95%CI 1.069-1.083,P<0.001)、SOFA评分(HR=1.035,95%CI 1.015-1.056,P<0.001)和CCI评分(HR=1.135,95%CI 1.115-1.155,P<0.001)是28天死亡的独立危险因素;年龄>65岁(HR=0.892,95%CI 0.801-0.994,P=0.039)和男性(HR=0.735,95%CI 0.669-0.808,P<0.001)为保护因素。
- ROC曲线分析:去甲肾上腺素等效评分预测28天死亡的AUC为0.743(95%CI 0.730-0.756),与APACHE II评分(AUC=0.742,95%CI 0.729-0.755)和平均动脉压/去甲肾上腺素等效评分比值(AUC=0.738,95%CI 0.725-0.751)相当(均P>0.05),优于SOFA评分(AUC=0.609,95%CI 0.594-0.624)、CCI评分(AUC=0.658,95%CI 0.644-0.673)、休克指数(AUC=0.613,95%CI 0.597-0.629)和舒张压/去甲肾上腺素等效评分比值(AUC=0.735,95%CI 0.721-0.748)(均P<0.05)。
- Kaplan-Meier生存曲线分析:去甲肾上腺素等效评分≤0.120者28天累积生存率显著高于>0.120者(Log-Rank检验:χ2=832.449,P<0.001);APACHE II评分≤22.5者28天累积生存率显著高于>22.5者(Log-Rank检验:χ2=848.600,P<0.001)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为去甲肾上腺素等效评分是脓毒症诊断后6小时内接受血管活性药物治疗患者28天死亡的独立危险因素,具有显著预测价值,可用于脓毒症管理的严重程度分层。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To elucidate the predictive value of norepinephrine equivalence (NEE) score on the 28-day death risk in patients with sepsis and provide evidence for its application in the diagnosis and treatment of sepsis and septic shock.
METHODS: A retrospective cohort study was conducted based on the data of patients with sepsis from Medical Information Mart for Intensive Care-IV 2.2 (MIMIC-IV 2.2). The patients who received vasoactive agents within 6 hours after the diagnosis of sepsis or septic shock were enrolled, and they were divided into survival and non-survival groups based on their 28-day outcomes. The baseline characteristics, vital signs, and treatment data were collected. Multivariate Cox regression analysis was performed to identify factors influencing the 28-day death risk. Receiver operator characteristic curve (ROC curve) was drawn to analyze the predictive value of various parameters on the 28-day death risk of septic patients. Kaplan-Meier survival curve was used to evaluate cumulative survival rate in patients classified by different quantitative parameters based on the cut-off values obtained from ROC curve analysis.
RESULTS: A total of 7 744 patients who met the Sepsis-3 diagnostic criteria and received vasopressor treatment within 6 hours post-diagnosis were enrolled, of which 5 997 cases survived and 1 747 died, with the 28-day mortality of 22.6%. Significant differences were observed between the two groups regarding age, gender, height, body weight, race, type of intensive care unit (ICU), acute physiology and chronic health evaluation II (APACHE II) score, sequential organ failure assessment (SOFA) score, Charlson comorbidity index (CCI) score, underlying comorbidities, and vital signs. Compared with the survival group, the non-survival group had poorer blood routine, liver and kidney function, coagulation function, blood gas analysis and other indicators. Multivariate Cox regression analysis revealed that age > 65 years old [hazard ratio (HR) = 0.892, 95% confidence interval (95%CI) was 0.801-0.994, P = 0.039] and male (HR = 0.735, 95%CI was 0.669-0.808, P < 0.001) were protective factors for 28-day death in patients with sepsis, and NEE score (HR = 1.040, 95%CI was 1.021-1.060, P < 0.001), shock index (HR = 1.840, 95%CI was 1.675-2.022, P < 0.001), APACHE II score (HR = 1.076, 95%CI was 1.069-1.083, P < 0.001), SOFA score (HR = 1.035, 95%CI was 1.015-1.056, P < 0.001), and CCI score (HR = 1.135, 95%CI was 1.115-1.155, P < 0.001) were independent risk factors for 28-day death in septic patients. ROC curve analysis showed that the area under the ROC curve (AUC) of NEE score for predicting the 28-day death risk of septic patients was 0.743 (95%CI was 0.730-0.756), which was comparable to the predictive value of APACHE II score (AUC = 0.742, 95%CI was 0.729-0.755) and ratio of mean arterial pressure (MAP)/NEE score (MAP/NEE; AUC = 0.738, 95%CI was 0.725-0.751, both P > 0.05), and better than SOFA score (AUC = 0.609, 95%CI was 0.594-0.624), CCI score (AUC = 0.658, 95%CI was 0.644-0.673), shock index (AUC = 0.613, 95%CI was 0.597-0.629) and ratio of diastolic blood pressure (DBP)/NEE score (DBP/NEE; AUC = 0.735, 95%CI was 0.721-0.748, all P < 0.05). According to the cut-off values of APACHE II and NEE scores obtained from ROC curve analysis, the patients were stratified for Kaplan-Meier survival curve analysis, and the results showed that the 28-day cumulative survival rate in the septic patients with an APACHE II score ≤ 22.5 was significantly higher than that in those with an APACHE II > 22.5 (Log-Rank test: χ2 = 848.600, P < 0.001), and the 28-day cumulative survival rate in the septic patients with an NEE score ≤0.120 was significantly higher than that in those with an NEE score > 0.120 (Log-Rank test: χ2 = 832.449, P < 0.001).
CONCLUSIONS: NEE score is an independent risk factor for 28-day death in septic patients who received vasoactive treatment within 6 hours of diagnosis and possesses significant predictive value. It can be used for severity stratification in sepsis management.
参考来源
- Li W, Wang J, Zheng Q, et al. [Predictive value of norepinephrine equivalence score on the 28-day death risk in patients with sepsis: a retrospective cohort study]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2025. PMID: 40814704. doi:10.3760/cma.j.cn121430-20240413-00341
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。